Home » Stocks » SVRA

Savara, Inc. (SVRA)

Stock Price: $1.09 USD -0.06 (-4.82%)
Updated Oct 28, 2020 12:43 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 58.73M
Revenue (ttm) n/a
Net Income (ttm) -68.93M
Shares Out 54.13M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.09
Previous Close $1.14
Change ($) -0.06
Change (%) -4.82%
Day's Open 1.12
Day's Range 1.05 - 1.12
Day's Volume 178,328
52-Week Range 0.69 - 5.48

More Stats

Market Cap 58.73M
Enterprise Value n/a
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 54.13M
Float 40.10M
EPS (basic) -1.48
EPS (diluted) -1.37
FCF / Share -0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.03M
Short Ratio 4.60
Short % of Float 2.57%
Beta 1.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.76
Revenue n/a
Operating Income -69.46M
Net Income -68.93M
Free Cash Flow -42.23M
Net Cash 74.75M
Net Cash / Share 1.38
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.22%
ROE -70.13%
ROIC -66.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(308.29% upside)
Current: $1.09
Target: 4.43
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth---640.74%-
Gross Profit---0.400.05
Operating Income-79.03-70.05-29.96-10.95-5.92
Net Income-78.17-61.52-29.80-10.92-9.00
Shares Outstanding40.0333.3017.521.960.97
Earnings Per Share-1.95-1.85-1.76-5.62-9.48
Operating Cash Flow-45.12-39.28-28.23-8.37-4.78
Capital Expenditures-0.15-0.14-0.50-0.01-
Free Cash Flow-45.27-39.42-28.73-8.38-4.78
Cash & Equivalents12211194.3113.37-
Total Debt25.1124.5315.344.47-
Net Cash / Debt96.6586.3078.988.90-
Book Value102108119-35.88-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Savara, Inc.
Country United States
Employees 46
CEO Matthew Pauls

Stock Information

Ticker Symbol SVRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SVRA


Savara operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.